News | August 30, 2012

Advanced CT Scans Match Accuracy of Stress Tests and Catheterization to Assess Coronary Blockages

Results of study from 16 hospitals in eight countries presented at international meeting

August 30, 2012 — An ultra-fast, 320-detector computed tomography (CT) scanner can accurately sort out which people with chest pain need – or don’t need – an invasive procedure such as cardiac angioplasty or bypass surgery to restore blood flow to the heart, according to an international study. Results of the study, which involved 381 patients at 16 hospitals in eight countries, were presented at the European Society of Cardiology Congress in Munich, Germany, on Aug. 28.

“The CORE 320 study is the first prospective, multicenter study to examine the diagnostic accuracy of CT for assessing blockages in blood vessels and determining which of those blockages may be preventing the heart from getting adequate blood flow,” said Joao A. C. Lima, M.D., senior author of the study and professor of medicine and radiology at the Johns Hopkins University School of Medicine. “We found an excellent correlation in results when we compared the 320-detector CT testing with the traditional means of assessment using a stress test with imaging and cardiac catheterization.”

The study findings, said Lima, would apply to people who have chest pain but are not having a heart attack. Many people in that situation are sent to a cardiac catheterization laboratory for further evaluation with angiography, an invasive test to look for blockages in the coronary arteries using dye and special X-rays. About 30 percent of people who have such catheterization are found to have minimal disease or no blockage requiring an intervention to open or bypass the vessel.

Lima explained that a nuclear medicine stress test with imaging, known as SPECT (single-photon emission computed tomography), shows reduced blood flow to the heart without indicating the number or specific location of blockages.

The 381 patients who completed the study had traditional SPECT tests and invasive angiography. They also had two types of tests with a noninvasive 320-detector CT scanner. In the first CT test, the scanner was used to see the anatomy of vessels to assess whether and where there were blockages (angiography). Then, in a second CT test with the same machine, patients were given a vasodilator, a medicine that dilates blood vessels and increases blood flow to the heart in ways similar to what happens during a stress test (CT perfusion [CTP])

According to lead author Carlos E. Rochitte, M.D., a cardiologist at the Instituto do Coracao in Sao Paulo, Brazil, “We found that the 320-detector CT scanner allowed us to see the anatomy of the blockages as well as determine whether the blockages were causing a lack of perfusion to the heart. We were therefore able to correctly identify the patients who needed revascularization within 30 days of their evaluation.”

“Many patients are sent for an angioplasty when they may not need it. Our ultimate goal is to have more certainty about which patients having chest pain – without evidence of a heart attack – need an invasive procedure to open an arterial blockage,” said cardiologist Richard George, M.D., assistant professor of medicine at the Johns Hopkins University School of Medicine and a co-author of the study. “The CTP test added significant information about the patients’ conditions and boosted our ability to identify those whose blockages were severe enough to reduce blood flow to the heart.”

The 320-slice detector provides a complete picture of the heart by making just one revolution around the body. The researchers say the two tests combined – CTA and CTP – still produce less radiation than a scan with the 64-detector in widespread use today. “In our study, the amount of radiation exposure to patients from the two 320-detector CT scanner tests was half the amount they received as a result of the traditional evaluation methods – the angiogram and nuclear medicine stress test combined,” says Lima.

The researchers will continue to follow the patients in the study for up to five years, looking for any heart-related events such as heart attacks, as well as hospital admissions, procedures or surgeries.

Hospitals that participated in the CORE 320 study are located in the United States, Germany, Canada, Brazil, the Netherlands, Denmark, Japan and Singapore. Images obtained during the study were evaluated in core laboratories at Johns Hopkins and at the Brigham and Women’s Hospital in Boston. The study was sponsored by Toshiba Medical Systems.

Johns Hopkins researchers collaborated with Toshiba on the development of the 320-detector CT scanner used in the study. In 2007, Johns Hopkins was one of three sites that participated in worldwide beta testing of the scanner that served as the prototype of the 320-detector system. Feedback provided by Johns Hopkins researchers was instrumental in the development of the scanner, which is now the only 320-detector CT scanner on the market.

For more information: www.hopkinsmedicine.org

Related Content

News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
Overlay Init